- Business Wire•3 days agoRosetta Genomics Selected by a Global Pharmaceutical Company to Supply FISH Testing Services for Clinical Study in Prostate Cancer
Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that the Company has entered into a services agreement with an unnamed global pharmaceutical company to provide Fluorescence in Situ Hybridization testing services for a clinical study the pharmaceutical company is conducting in prostate cancer.
- Business Wire•23 days agoRosetta Genomics Expands Molecular Diagnostics Test Menu with Launch of OncoGxSelect™ from Admera Health
Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based and other molecular diagnostics, announces the launch of OncoGxSelect™, a next generation sequencing -based test that detects somatic mutations frequently found in cancers and provides actionable results to help guide therapeutic decisions related to targeted cancer therapies.
- Business Wire•25 days agoRosetta Expands Managed Care Coverage with New Preferred Provider Agreement with Galaxy Health Network for Entire Suite of Diagnostic Tests and Services
Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based and other molecular diagnostics, today announces a new participation agreement with Preferred Provider Organization , Galaxy Health Network, as a preferred laboratory provider.
Rosetta Genomics, Ltd. (ROSG)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Ask||1.10 x 100|
|Day's Range||1.00 - 1.04|
|52wk Range||0.71 - 3.10|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-0.98|
|Avg Vol (3m)||320,420|
|Dividend & Yield||N/A (N/A)|